Considerations for Choosing Between Newer Agents in R/R B-Cell ALL

In the past 5 years, 3 new treatment options have emerged to treat patients with relapsed or refractory acute lymphoblastic leukemia, providing hope for patients with this disease, but also ...

In the past 5 years, 3 new treatment options have emerged to treat patients with relapsed or refractory acute lymphoblastic leukemia, providing hope for patients with this disease, but also raising clinical questions of how to choose among these agents and what is the best option for the patient at which time.

---

Write the first review

Resource tags